Centene will contribute up to $100 million over 10 years to fund research into Alzheimer's disease, breast cancer, diabetes, and obesity at WashU.
Patients within the project and their physicians will be able to access Genome Medical's genetic specialists to address concerns and incorporate genetic information into care.
Startup AiLife Diagnostics is contributing its NGS analysis, interpretation, and reporting pipelines to BGI's $600 DNBseq WGS assay.
LifeMap says that the newly announced partnership will improve literature searches for users of its GeneCards knowledge base and TGex clinical genomics platform.
The partners will develop patient-specific assays based on ArcherDx's anchored multiplex PCR technology to track disease recurrence in lung cancer patients.
Horizon will help develop the cell line-derived reference material, St. George's will provide clinical samples, and the EMQN will run a validation study.
Cambridge Cancer Genomics will contribute AI, liquid biopsy technology, and a TMB sequencing panel to broaden access to cancer immunotherapies in the UK.
The Genomics4RD platform is focused on data harmonization from research collaborations across Canada, but its developers are eyeing a future in the clinical market.
The Common Infrastructure for National Cohorts in Europe, Canada, and Africa (CINECA) project looks to harmonize ontologies and create an interoperability platform for global genomics research.
Using BGI's sequencing technology, the firms plan to commercialize Natera's Signatera test in China and to develop reproductive health tests in "select markets."
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.